Xenon Inhibits Excitatory but Not Inhibitory Transmission in Rat Spinal Cord Dorsal Horn Neurons by Stefan K Georgiev et al.
MOLECULAR PAIN
Georgiev et al. Molecular Pain 2010, 6:25
http://www.molecularpain.com/content/6/1/25
Open AccessR E S E A R C HResearchXenon inhibits excitatory but not inhibitory 
transmission in rat spinal cord dorsal horn neurons
Stefan K Georgiev1, Hidemasa Furue2,3, Hiroshi Baba1 and Tatsuro Kohno*1,4
Abstract
Background: The molecular targets for the promising gaseous anaesthetic xenon are still under investigation. Most 
studies identify N-methyl-D-aspartate (NMDA) receptors as the primary molecular target for xenon, but the role of α-
amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid (AMPA) receptors is less clear. In this study we evaluated the 
effect of xenon on excitatory and inhibitory synaptic transmission in the superficial dorsal horn of the spinal cord using 
in vitro patch-clamp recordings from rat spinal cord slices. We further evaluated the effects of xenon on innocuous and 
noxious stimuli using in vivo patch-clamp method.
Results: In vitro, xenon decreased the amplitude and area under the curve of currents induced by exogenous NMDA 
and AMPA and inhibited dorsal root stimulation-evoked excitatory postsynaptic currents. Xenon decreased the 
amplitude, but not the frequency, of miniature excitatory postsynaptic currents. There was no discernible effect on 
miniature or evoked inhibitory postsynaptic currents or on the current induced by inhibitory neurotransmitters. In vivo, 
xenon inhibited responses to tactile and painful stimuli even in the presence of NMDA receptor antagonist.
Conclusions: Xenon inhibits glutamatergic excitatory transmission in the superficial dorsal horn via a postsynaptic 
mechanism. There is no substantial effect on inhibitory synaptic transmission at the concentration we used. The 
blunting of excitation in the dorsal horn lamina II neurons could underlie the analgesic effect of xenon.
Background
Xenon has an excellent anaesthetic profile and if used
with an elaborate low-flow delivery system, xenon has the
potential to become a main-line anaesthetic [1-3], replac-
ing nitrous oxide in balanced anaesthesia or it could even
be used as a mono-anaesthetic. Accumulating reports on
xenon's organ-protective properties [4,5] suggest it may
have promising use in high-risk patients. Significant
progress has been made toward elucidating how xenon
produces anaesthesia and several potential molecular tar-
gets have been identified. Current evidence strongly indi-
cates that xenon inhibits excitatory glutamatergic
signalling, but it is unclear which receptor subtype is
involved in its anaesthetic action [6]. Most studies agree
on N-methyl-D-aspartate (NMDA) receptor inhibition
[7,8], but reports on xenon's effects on α-amino-3-
hydroxy-5-methyl-4-isoxazole-4-propionic acid (AMPA)
receptors are contradictory [9,10]. A recent study using
murine brain slices reported inhibition of both NMDA
and AMPA receptors in amygdala neurons, a brain region
related to anaesthetic-induced amnesia, modulation of
pain perception and emotions [11]. However, pain pro-
cessing is not confined to a single brain region, which
makes us think it is appropriate to investigate the effect of
xenon at the gate, that is, the superficial dorsal horn of
the spinal cord. The spinal cord was proposed as site of
the analgesic effect of xenon when neuronal responses to
touch and pinch, obtained by extracellular recordings,
were suppressed by the inert gas in spinal cord intact [12]
and transected [13] cats, but this hypothesis was not fur-
ther investigated in detail. Spinal cord slice preparations
with attached dorsal roots show preserved local neuronal
networks and afferent inputs, and thus, have proved use-
ful in analyzing the mechanisms of pain transmission and
drug pharmacology. The aim of the present study was to
characterize the effects of xenon on excitatory and inhib-
itory synaptic transmission in dorsal horn lamina II (sub-
stantia gelatinosa, SG), the first processing centre in the
nociceptive information flow.
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Effects of xenon on excitatory synaptic transmission 
revealed by in vitro patch-clamp recordings
Xenon did not directly affect postsynaptic membrane
properties, because the amount of holding current
required to maintain the neurons at -70 or 0 mV (%
change = 3.9 ± 0.3; n = 55) and the resting membrane
potential (control, -65.1 ± 0.7 mV vs. xenon, -65.3 ± 0.8
mV, n = 15, P = 0.7) were unaffected by xenon.
We first investigated the effects of xenon on evoked
excitatory postsynaptic currents (eEPSCs). Electrical
stimulation of the dorsal root evoked inward synaptic
currents at -70 mV. These currents are believed to be
mediated exclusively by AMPA receptors, because they
were almost completely blocked by 6-cyano-7-nitroqui-
noxaline-2,3-dione (CNQX, 10 μM, current amplitude =
4.0 ± 0.5% of control, n = 4, data not shown). Only data
meeting the criteria for monosynaptic currents were fur-
ther analyzed. Xenon decreased the amplitude of Aδ-
fibre intensity stimulation-evoked current to 60 ± 3% of
control (n = 10, P < 0.01; Fig. 1A, B) and the integrated
area to 59 ± 4% of control (n = 10, P < 0.01; data not
shown). The effect of xenon was typically noticeable
within 2-3 minutes following xenon application, reached
its maximum by 3 minutes and disappeared approxi-
mately 3 minutes after xenon's termination. Xenon simi-
larly decreased the current amplitude to 57 ± 3% of the
control level (n = 9, P < 0.01; Fig. 1A, C) and the inte-
grated area to 58 ± 3% (n = 9, P < 0.01; data not shown)
for C-fibre mediated responses in all tested neurons.
Exogenous agonist-induced currents are representative
for activation of postsynaptic receptors. Exogenous appli-
cation of NMDA (50 μM, 30 s) elicited an outward cur-
rent at +40 mV (Fig. 2A). In the presence of xenon, but
not nitrogen, the mean amplitude of NMDA-induced
current was reversibly reduced to 60 ± 3% (n = 8, P < 0.01;
Fig. 2A, B) and the integrated area to 63 ± 2% (n = 8, P <
0.01; Fig. 2B) of control values. Bath-applied AMPA (10
μM, 30 s) induced an inward current at -70 mV. During
xenon application the peak amplitude and integrated area
of AMPA-induced current decreased to 61 ± 3% (n = 7, P
< 0.01) and 63 ± 2% (n = 7, P < 0.01; Fig. 2C, D) of the
control values, respectively, and returned to initial values
after washout.
Miniature excitatory postsynaptic currents (mEPSC)
were isolated by adding tetrodotoxin (TTX, 1 μM) to the
Figure 1 Effect of xenon on eEPSCs. A - Excitatory post synaptic currents evoked at holding potential (HP) = -70 mV by primary afferents electrical 
stimulation recruiting Aδ- (left) and C-fibres (right) before (black), during (dark grey) and after (light grey) xenon application. Five consecutive traces 
are shown for each modality. Note the decrease in amplitude during xenon application. B - Xenon reversibly decreased the mean amplitude of mono-
synaptic currents evoked by Aδ- (left, n = 10) and C- (right, n = 9) afferent fibre stimulation.
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Figure 2 Exogenous agonist-induced currents inhibited by xenon. A - Representative traces showing NMDA (50 μM, 30 s)-induced outward cur-
rents at HP = +40 mV, which were reversibly reduced by xenon (50%). Drug application is marked with bars. B - Xenon decreased the amplitude and 
integrated area of NMDA-induced currents in lamina II neurons (n = 8). *P < 0.05 compared with control. C - AMPA (10 μM, 30 s)-induced inward cur-
rents at HP = -70 mV, which were reversibly reduced by xenon (50%). D - Xenon decreased the amplitude and integrated area of NMDA-induced cur-
rents in lamina II neurons (n = 7). *P < 0.05 compared with control.
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mEPSC amplitude decreased to 81 ± 5% of control (n =
16, P < 0.01; Fig. 3A, B). In 12 of 16 neurons tested, the
cumulative histograms of amplitude distribution were
significantly shifted to the left after perfusion with xenon
(Fig. 3C). The mean relative mEPSC frequency remained
unchanged (100 ± 6% of control, n = 16, P = 0.2; Fig. 3A-
C), as did the decay time constant (100 ± 2% of control, n
= 16, P = 0.8, data not shown). When the cumulative his-
tograms of the inter-event intervals were analyzed by
Kolmogorov-Smirnov test, there was an increase in inter-
event intervals in two neurons and a decrease in three,
but in the majority (11/16) of neurons, the inter-event
intervals were not affected. Xenon-induced changes in
mEPSC amplitude and frequency usually disappeared
within 3-4 minutes after discontinuation of the drug.
Effects of xenon on excitatory synaptic transmission 
revealed by in vivo patch-clamp recordings
We further looked to confirm the in vitro-obtained data
with in vivo recordings. Light brushing or pinching with
forceps of a specific area of the hind limb produced a bar-
rage of EPSCs, which persisted during the whole stimulus
and terminated with its termination (Fig. 4A, C). Both
mean amplitude (61 ± 4% of control, n = 4, P < 0.01; Fig.
4B) and integrated area (56 ± 6% of control, n = 4, P <
0.01; Fig. 4B) of touch-evoked responses were inhibited
by xenon. Amplitude (60 ± 3% of control, n = 6, P < 0.01;
Fig. 4D) and integrated area (61 ± 3% of control, n = 6, P <
0.01; Fig. 4D) of pinch-evoked responses were similarly
inhibited by xenon. We further investigated the nature of
these responses by applying the NMDA receptor antago-
nist D-2-amino-5-phosphonovaleric acid (APV, 50 μM)
prior and during xenon application. In the presence of
APV, xenon similarly inhibited the responses to touch
(amplitude: 64 ± 2% of control, n = 3, P < 0.01; integrated
area: 62 ± 2% of control, n = 3, P < 0.01, see additional file
1) and pinch (amplitude: 65 ± 3% of control, n = 4, P <
0.01; integrated area: 61 ± 3% of control, n = 4, P < 0.01;
see additional file 2) stimuli. The spontaneous EPSCs as
well as touch (amplitude: 5 ± 1% of control, n = 2; inte-
grated area: 1 ± 1% of control, n = 2) and pinch (ampli-
tude: 6 ± 1% of control, n = 2; integrated area: 3 ± 1% of
control, n = 2) stimulation-evoked EPSCs almost com-
pletely disappeared in the presence of CNQX (20 μM).
Effects of xenon on inhibitory synaptic transmission 
revealed by in vitro patch-clamp recordings
The next step was to examine whether xenon modulates
inhibitory synaptic transmission in SG neurons at a hold-
ing potential of 0 mV. The amplitude of the current elic-
ited by exogenous application of GABA (1 mM, 30 s) was
not affected by xenon (99 ± 3% of control, n = 8, P = 0.7;
Fig. 5A), and nor was the integrated area (102 ± 5% of
control, n = 8, P = 0.6; Fig. 5A). Glycine (1 mM, 30 s)-
induced current amplitude (102 ± 5% of control, n = 8, P
= 0.7; Fig. 5B) and integrated area (101 ± 5% of control, n
= 8, P = 0.9; Fig. 5B) were also not affected by xenon.
Focal stimulation near the recorded neuron elicited
monosynaptic inhibitory postsynaptic currents (IPSCs).
The peak amplitude (100 ± 4% of control, n = 6, P = 0.9;
Fig. 5C), integrated area (101 ± 5% of control, n = 6, P =
0.8; Fig. 5C) and decay time (99 ± 3% of control, n = 6, P =
0.6, not shown) did not change in the presence of xenon.
The above evoked IPSC are known to be mediated by
GABA and glycine receptors, but since no effect was
observed on the compound eIPSCs, there were no further
studies done. Adding TTX (1 μM) to the Krebs solution
allowed for recording of mIPSCs. During xenon applica-
tion, the mIPSC mean amplitude was 97 ± 4% of the con-
trol level (n = 9, P = 0.8; Fig. 5D), mean frequency was 102
± 6% of the control level (n = 9, P = 0.8; Fig. 5D), and
decay time was 101 ± 2% of the control level (n = 9, P =
0.9, not shown). Analysis of cumulative distribution his-
tograms showed a decrease in mIPSC amplitude in one
neuron, increase in another and no change in seven.
Inter-event intervals decreased in two neurons and
increased in one, but remained unchanged in the major-
ity (6/9) of tested cells.
Discussion
In this study we investigated the effects of xenon on excit-
atory and inhibitory synaptic transmission in the superfi-
cial dorsal horn using in vitro and in vivo patch-clamp
methods. Xenon inhibited excitatory synaptic transmis-
sion by postsynaptic inhibition of both NMDA and
AMPA receptors, but had no effect on inhibitory synaptic
transmission in adult rat dorsal horn neurons.
We used 50% xenon in our experiments for technical
and financial reasons. Because the minimal alveolar con-
centration (MAC) of xenon is estimated to be 63-71% in
humans and between 86% [14] and 161% [15] in rats, the
concentration we used (50% xenon) is 0.31-0.58 rat MAC.
Although this concentration is insufficient to induce
anaesthesia, xenon is known to have analgesic properties
even at sub-anaesthetic (0.3 MAC) concentrations in
humans [16,17] and in rats [18], so we believe that this
xenon concentration is sufficient to modulate nociceptive
synaptic transmission at the dorsal horn level.
The role of ionotropic glutamatergic receptors as
anaesthetic targets has emerged during the last decade
and NMDA receptors have had a central place in most
reports. Several studies have demonstrated that xenon
inhibits NMDA receptors in various non-neuronal [19]
and neuronal [7,9] preparations. Our results confirm the
inhibitory action of xenon on NMDA receptors and
extend this to SG neurons. The inhibition of NMDA
receptor-mediated signalling in dorsal horn neurons
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Figure 3 Xenon decreased mEPSC amplitude, but not mEPSC frequency. A - Two-scale traces of mEPSC recorded at HP = -70 mV in the presence 
of tetrodotoxin (1 μM) before, during and after xenon application. B - The effect of xenon on miniature excitatory postsynaptic current (mEPSC) am-
plitude (n = 16) and frequency (n = 16). *P < 0.05 compared with control. C - Cumulative histograms of mEPSC amplitude (left) and inter-event intervals 
(right) from a representative neuron showing the shift to the left of mEPSC amplitude under xenon exposure. Control trace was calculated from 470 
events and xenon trace was calculated from 490 events.
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Figure 4 Xenon inhibited the responses to touch and pinch in vivo. A - Representative traces showing the decrease in the response to light touch 
of the hind limb during xenon application (HP = -70 mV) recorded using in vivo patch-clamp method. B - Diagram showing the reversible decrease in 
mean amplitude and integrated area of the touch response during xenon application (n = 4). *P < 0.05 compared with control. C - Response to skin 
fold pinch during xenon application. D - The mean amplitude and integrated area of pinch-evoked EPSCs decreased in the presence of xenon (n = 6). 
n is the number of neurons.
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indirectly, through decreasing the sensory input to the
ventral horn, contribute to the immobilizing action of
xenon. Additionally, NMDA receptor antagonism by
xenon could prevent plasticity-related phenomena like
central sensitization or excitotoxicity. Actually, xenon has
prevented the development of long-term potentiation
[20], presumably by inhibiting NMDA or/and AMPA sig-
nalling in the superficial dorsal horn. An fMRI study
demonstrated that sub-anaesthetic doses of xenon sup-
pressed the enhanced responsiveness in pain-related
brain areas induced by repeated painful stimulation [21].
In another study, xenon protected against neuronal injury
in an NMDA excitotoxicity model [22]. Future investiga-
tions should determine whether xenon has a beneficial
effect in preventing or reversing central sensitization
after nerve injury or other chronic pain states.
AMPA receptors contribute to the acute spinal process-
ing of both nociceptive and non-nociceptive inputs in the
spinal cord [23,24]. Not only have they been implicated in
analgesic action of anaesthetics [25,26], but accumulating
evidence indicates that they contribute to synaptic plas-
ticity associated with chronic pain states [27,28]. There is
still an ongoing controversy whether xenon inhibits
AMPA receptors. Different receptor composition proba-
bly underlies the variability in effect among tissues. Initial
reports using hippocampal cultures [7,9] presumed lack
of effect of xenon on AMPA receptors, because the effect
of xenon on compound EPSCs closely mimicked the
effect of a NMDA receptor antagonist. Another study
using recombinant receptors [29] proposed that xenon
induced inhibition of AMPA current is due to desensiti-
zation, since such inhibition was not observed when glu-
tamate was applied briefly in high concentration to
receptors containing GluR1 or GluR4 subunits. However,
heteromeric GluR1/GluR2 receptors could not be tested
with rapid pulses of glutamate in the above study. Since
AMPA receptors formed by GluR1 and GluR2 subunits
Figure 5 Xenon did not affect inhibitory synaptic transmission in lamina II neurons. Representative traces and diagrams showing no change in 
amplitude and integrated area of the currents induced by exogenous GABA (A) or glycine (B) in the presence of xenon. C - Focal stimulation induced 
inhibitory postsynaptic currents before (grey) and during (black) xenon application. Neither amplitude nor integrated area changed in the presence 
of xenon. D - Trace and diagram showing the lack of an effect of xenon on the mean amplitude or frequency of miniature inhibitory postsynaptic 
currents.
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horn [30], the sensitivity of AMPA receptors there could
be different. Spinal cord slice-preparation allows record-
ing of spontaneous and evoked synaptic events from neu-
rons with native receptors and neurotransmitters and a
relatively spared neuronal network, thereby eliminating
unwanted artefacts such as questionable subunit compo-
sition and desensitization concerns. Our data from in
vitro experiments clearly indicate that xenon inhibits
AMPA receptors located on SG neurons receiving direct
mono synaptic input from the primary afferent Aδ- and
C-fibres, thus decreasing the amount of excitatory flow to
the CNS.
These data were confirmed by in vivo experiments, in
which xenon decreased the responses to innocuous and
noxious stimuli. Moreover, the inhibitory effect of xenon
did not change in the presence of APV, an NMDA recep-
tor antagonist. However, adding CNQX resulted in
almost complete vanishing of spontaneous and evoked
EPSCs, suggesting that the above responses, recorded at
holding potential of -70 mV, are predominantly AMPA
receptor mediated.
The sensation for pinch is carried by Aδ- and C-fibres
and touch could be relayed by Aβ-, Aδ- or C-fibres [31].
However, the monosynaptic input from Aβ-fibres is
extremely rare in SG neurons under physiological condi-
tions. Hypothesizing that the response to touch is pre-
dominantly conveyed by fine myelinated or unmyelinated
fibres, the inhibition of the touch response by xenon
would concomitantly inhibit the conduction of noxious
responses since the same fibres convey the sensation of
pain.
Taken together, our in vitro and in vivo data support the
accumulating evidence from other studies using cortical
cultures [10], amygdala slices [11] and behavioural tests
on C. elegans[32] that AMPA receptors are also targets
for xenon. It is difficult from our data to compare the sen-
sitivity of the two types of ionotropic glutamate NMDA
and AMPA receptors to xenon, but amygdala neurons
[11] showed similar degree of inhibition of both receptors
by several concentrations of xenon. Moreover, these
receptors were similarly inhibited by xenon according to
a freshly published study on SG and cortical neurons [33].
Since the rats for in vivo experiments were already
anesthetized when xenon was applied, there is a possibil-
ity that urethane would affect the xenon action. Indeed, a
modest potentiation of recombinant GABA and glycine
receptors and modest inhibition of NMDA and AMPA
receptors by urethane has been previously reported [34].
However, data from experiments with recombinant
receptors sometimes fail to be confirmed by experiments
using native receptors, like in the following study where
urethane was shown not to affect the evoked Aδ- and C-
fibre mediated EPSCs in spinal cord slice preparation
[35]. Finally, the in vivo results in our study are in agree-
ment with the results in vitro, where urethane was not
used. Therefore it seems that urethane is unlikely to
interfere with the effect of xenon.
There is an apparent difference in the extent of inhibi-
tion between evoked and miniature EPSCs. The purpose
of investigation of miniature postsynaptic currents is to
differentiate between pre- and post-synaptic site of
action. The nature of the miniature events is different
from that of evoked ones. Furthermore, the magnitude of
drug effect could also be different. In addition, there is a
detection threshold for the amplitude of mEPSCs, which
implies the possibility that some events just above the
threshold would become sub-threshold during xenon
application leading to some underestimation of the
degree of inhibition.
Many inhalational and venous anaesthetics potentiate
inhibitory synaptic transmission, but we did not find a
substantial effect of xenon on inhibitory synapses in the
superficial dorsal horn. Xenon has been shown to
increase the efficacy of GABA at recombinant receptors
[36], but there are at least two striking differences other
than receptor composition itself between our study and
Hapfelmeyer's. We used 50% xenon vs. 100% and we used
10-3 M GABA vs. 10-5-10-7 M. Our results are consistent
with most other reports, which agree on the negligible
effect of xenon on GABA and glycine receptors
[7,11,19,37].
Xenon was found to possess an equal or superior anal-
gesic effect to nitrous oxide in MAC-equivalent concen-
trations in humans [16,17]. Although a quantitative
comparison is beyond the scope of this work, we found
that the 50% xenon used here and the 50% nitrous oxide
used in our previous work [38] had comparable effects on
glutamate receptors in SG neurons. Moreover, besides
glutamate receptor inhibition in the dorsal horn, the
descending noradrenergic system also participates in
nitrous oxide-induced analgesia. That said, actions of
xenon on higher centres and/or other targets like acetyl-
choline and serotonin receptors, two-pore domain potas-
sium channels or plasma membrane Ca2+-adenosine
triphosphatase may also contribute to xenon's analgesic
effect.
Conclusions
In conclusion, our data identifies NMDA and AMPA
receptors in SG neurons as molecular targets of xenon,
and suggests that the inhibition of these receptors under-
lies the anti-nociceptive action of xenon.
Methods
In vitro patch-clamp recordings
The methods used for the current experiment were simi-
lar to those used in our previous study [39] and were
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gata University Graduate School of Medical and Dental
Sciences. Briefly, male Wistar rats (200-300 g) were
anaesthetized with urethane (1.5 g/kg, i.p.). A dorsal
laminectomy was performed and a lumbosacral segment
of the spinal cord was removed. A 500-μm-thick trans-
verse slice was cut sparing the left L4 dorsal root, on a
DTK-1500 vibrating microslicer (Dosaka, Japan), and
placed on a nylon mesh in the recording chamber. The
slice was perfused with Krebs solution (10-15 ml/min)
equilibrated with a 95% O2, 5% CO2 gas mixture at 36°C
(See additional file 3). The composition of the Krebs solu-
tion was as follows (in mM): NaCl 117, KCl 3.6, CaCl2 2.5,
MgCl2 1.2, NaH2PO4 1.2, NaHCO3 25 and D-glucose 11.
Whole-cell patch-clamp recordings were obtained from
SG neurons in voltage-clamp mode with patch pipettes
pulled from thin-walled glass capillaries (1.5 mm o.d.,
World Precision Instruments) to have a tip resistance of
5-8 MO. The patch-pipette solution contained (in mM):
Cs2SO4 110, CaCl2 0.5, MgCl2 2, EGTA 5, HEPES 5, tetra-
ethyl ammonium (TEA) 5, ATP (Mg salt) 5. The SG was
visually identified as a translucent band and the tip of the
recording electrode was directed toward its centre.
Signals were amplified with an Axopatch 200B ampli-
fier (Molecular Devices) and were filtered at 2 kHz and
digitized at 5 kHz. All experiments were performed in
voltage-clamp mode. Holding potential was set to -70 mV
for recording exogenous AMPA current and miniature
and evoked EPSC. Exogenous NMDA current was
recorded at +40 mV. Exogenous GABA and glycine cur-
rents, as well as miniature and evoked IPSCs, were
recorded at 0 mV.
Excitatory synaptic currents were evoked by dorsal root
electrical stimulation, performed at relatively low inten-
sity for Aδ-fibres (30-100 μA, 0.1 ms), and at relatively
higher intensity and longer duration for C-fibres (200-700
μA, 0.5 ms). Differentiation of synaptic responses into
Aδ- and C-fibres was based on a combination of response
threshold and conduction velocities (5-8 m/s for Aδ-
fibres; 0.5-1.0 m/s for C-fibres [38]). Evoked EPSCs that
displayed a constant latency and lack of failures with high
frequency stimulation (20 Hz for Aδ-fibres and 1 Hz for
C-fibres) were classified as monosynaptic. Inhibitory syn-
aptic responses were evoked by focal stimulation of SG
interneurones with a monopolar silver wire electrode
(diameter = 50 μm), insulated except for the tip and
located within 100 μm of the recorded neuron [40].
In vivo patch-clamp recordings
As previously described [41,42], male Wistar rats aged 7-
8 weeks were anaesthetized, lumbar laminectomy was
performed at the level of L4 or L5, and then the animal
was placed in a stereotaxic apparatus. After removing the
dura mater and cutting into the arachnoid membrane a
window large enough to let pass a patch electrode, the
surface of the spinal cord was irrigated with 95% O2, 5%
CO2 equilibrated Krebs solution. Whole-cell patch-clamp
recordings were performed as described in the in vitro
section. The recorded neurons were identified as being in
the SG based on their morphological features revealed by
the depth of the neurons from the surface of the spinal
cord and on their electrophysiological properties [41].
The mechanical stimuli used were pinches of skin folds
with a toothed forceps and light touch of the surface of
skin or the hairs in the ipsilateral hind limb. The stimuli
were applied at the maximal response point of the respec-
tive receptive area and care was taken to stimulate the
same point during the recording. The amplitude of the
EPSCs during the stimulation were measured for a fixed
interval according to the stimulus duration (typically 5-8
sec), then averaged and compared to the control values
for each neuron. The area under the curve is a single
value calculated in pCLAMP10 (Molecular Devices). The
n values are the number of neurons.
Drugs and data analysis
Xenon was applied by bubbling through the perfusing
solution and was delivered through ultrathin polyethyl-
ene tubes. The solution was first saturated with the gas
mixture for 30 min and then applied to the slice for at
least 5 min prior to recordings. Xenon was mixed in a 1:1
ratio with a prefabricated gas containing 90% O2, 10%
CO2 so that the composition of the gas mixture was: 50%
Xe, 45% O2, and 5% CO2. In some experiments 50% nitro-
gen was used instead of xenon as a negative control.
NMDA (50 μM), AMPA (10 μM), GABA (1 mM) and gly-
cine (1 mM) were applied to the slice for 30 sec. In a sub-
set of experiments tetrodotoxin (TTX, 1 μM) was used to
isolate mEPSCs and mIPSCs. Drugs were purchased as
follows: xenon from TG Showa (Tokyo, Japan), NMDA,
AMPA, APV, CNQX, GABA, glycine from Sigma (USA)
and TTX from Wako (Japan).
Data were analyzed using pCLAMP10 (Molecular
Devices), GraphPad Prism 5 (GraphPad Software) and
Mini-analysis 6.0.3 (Synaptosoft) software. Data are pre-
sented as means ± SEM. Because most of the data met the
criteria for parametric tests, they were analyzed by Stu-
dent's paired t-tests, unless otherwise stated. For detec-
tion of mEPSCs and mIPSCs, the amplitude threshold
was defined as three times the noise level and the
detected events were subsequently visually confirmed.
The effect of xenon on the cumulative distribution of
mEPSC and mIPSC amplitudes and inter-event intervals
was analyzed using the Kolmogorov-Smirnov test. P <
0.05 was considered significant and is indicated by an
asterisk in the figures.
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Additional file 1 Xenon inhibited the responses to touch in vivo in the 
presence of APV. Representative traces of response to touch (A) in pres-
ence of APV (50 μM; B), APV and xenon (C), and APV and CNQX (20 μM) (D). 
Stimulus duration is marked with a bar. Responses to touch in the presence 
of APV had similar amplitude (98 ± 1%, n = 3) and integrated area (97 ± 2%, 
n = 3) compared to control. Xenon inhibited the response to touch (ampli-
tude (E): 64 ± 2%; area (F): 62 ± 2%, n = 3) even in the presence of APV. P < 
0.05 is indicated by an asterisk. The touch response was CNQX sensitive (D, 
E, F).
Additional file 2 Xenon inhibited the responses to pinch in vivo in the 
presence of APV. Representative traces of response to pinch (A) in the 
presence of APV (50 μM; B), APV and xenon (C), and APV and CNQX (20 μM) 
(D). Stimulus duration is marked with a bar. Responses to pinch in the pres-
ence of APV had similar amplitude (96 ± 5%, n = 4) and integrated area (97 
± 3%, n = 4) compared to control. Xenon inhibited the response to pinch 
(amplitude (E): 65 ± 3%; area (F): 61 ± 3%, n = 4) even in the presence of 
APV. P < 0.05 is indicated by an asterisk. The pinch response was also CNQX 
sensitive (D, E, F).
Additional file 3 Schematic representation of the experimental set-
ting for in vitro recordings. A spinal cord slice (scaled-up for clarity) is 
being continually perfused with artificial cerebrospinal liquid. Membrane 
currents are recorded from a lamina II neuron by perforating its cellular 
membrane with a recording pipette. Electrical stimulation of the dorsal root 
evokes postsynaptic currents, which after being amplified and digitalized, 
are recorded on a personal computer.
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